Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | STK11 K262Sfs*25 |
Therapy | Everolimus |
Indication/Tumor Type | gallbladder carcinoma |
Response Type | no benefit |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
STK11 K262Sfs*25 | gallbladder carcinoma | no benefit | Everolimus | Case Reports/Case Series | Actionable | In a clinical case study, treatment with Afinitor (everolimus) resulted in disease progression in a patient with gallbladder carcinoma harboring STK11 K262Sfs*25 and ATM S1905Ifs*25 who had previously progressed on Lynparza (olaparib) treatment after a 13 month progression-free survival (PMID: 32045060). | 32045060 |
PubMed Id | Reference Title | Details |
---|---|---|
(32045060) | Effectiveness of Olaparib Treatment in a Patient with Gallbladder Cancer with an ATM-Inactivating Mutation. | Full reference... |